S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
S&P 500   3,855.53 (+0.00%)
DOW   30,985.36 (+0.08%)
QQQ   328.62 (+0.16%)
AAPL   142.12 (-0.56%)
MSFT   231.76 (+0.97%)
FB   282.62 (+1.66%)
GOOGL   1,904.54 (+0.54%)
AMZN   3,321.51 (+0.84%)
TSLA   888.00 (+0.82%)
NVDA   538.75 (-1.35%)
BABA   263.74 (+0.90%)
CGC   34.98 (+6.29%)
GE   11.49 (+4.55%)
MU   80.57 (-0.87%)
AMD   94.84 (+0.75%)
NIO   59.60 (-0.65%)
T   29.44 (+1.13%)
F   11.20 (-0.80%)
ACB   10.60 (+4.33%)
BA   202.89 (-0.23%)
DIS   170.31 (-0.92%)
NFLX   563.79 (+1.26%)
GILD   66.74 (-2.08%)
Log in
NYSE:PFE

Pfizer Stock Forecast, Price & News

$37.43
+0.15 (+0.40 %)
(As of 01/26/2021 01:09 PM ET)
Add
Compare
Today's Range
$37.17
Now: $37.43
$37.59
50-Day Range
$36.48
MA: $37.76
$42.56
52-Week Range
$27.88
Now: $37.43
$43.08
Volume764,636 shs
Average Volume34.07 million shs
Market Capitalization$208.05 billion
P/E Ratio24.15
Dividend Yield4.16%
Beta0.7
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Myovant Sciences Ltd.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; a drug discovery collaboration with Sosei Group Corporation; and collaboration with LianBio. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer logo

MarketRank

Overall MarketRank

2.72 out of 5 stars

Medical Sector

5th out of 1,922 stocks

Pharmaceutical Preparations Industry

2nd out of 771 stocks

Analyst Opinion: 2.1Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323
Employees88,300
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.75 billion
Cash Flow$4.17 per share
Book Value$11.46 per share

Profitability

Net Income$16.27 billion

Miscellaneous

Outstanding Shares5,558,396,000
Market Cap$208.05 billion
Next Earnings Date2/2/2021 (Confirmed)
OptionableOptionable
$37.43
+0.15 (+0.40 %)
(As of 01/26/2021 01:09 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pfizer (NYSE:PFE) Frequently Asked Questions

How has Pfizer's stock been impacted by COVID-19?

Pfizer's stock was trading at $32.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PFE shares have increased by 15.9% and is now trading at $37.29.
View which stocks have been most impacted by COVID-19
.

Is Pfizer a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Pfizer stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
View analyst ratings for Pfizer
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Pfizer?

Wall Street analysts have given Pfizer a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pfizer wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer CEO Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among Pfizer's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Pfizer's next earnings date?

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Pfizer
.

How can I listen to Pfizer's earnings call?

Pfizer will be holding an earnings conference call on Tuesday, February 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its earnings results on Tuesday, October, 27th. The biopharmaceutical company reported $0.72 earnings per share for the quarter, topping analysts' consensus estimates of $0.71 by $0.01. The biopharmaceutical company earned $12.13 billion during the quarter, compared to the consensus estimate of $12.30 billion. Pfizer had a net margin of 17.85% and a trailing twelve-month return on equity of 24.88%. The firm's revenue was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share.
View Pfizer's earnings history
.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Friday, December 11th. Stockholders of record on Friday, January 29th will be paid a dividend of $0.39 per share on Friday, March 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.18%. The ex-dividend date of this dividend is Thursday, January 28th. This is a positive change from Pfizer's previous quarterly dividend of $0.38.
View Pfizer's dividend history
.

Is Pfizer a good dividend stock?

Pfizer pays an annual dividend of $1.52 per share and currently has a dividend yield of 4.16%. PFE has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Pfizer does not yet have a strock track record of dividend growth. The dividend payout ratio of Pfizer is 51.53%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Pfizer will have a dividend payout ratio of 49.67% next year. This indicates that Pfizer will be able to sustain or increase its dividend.
View Pfizer's dividend history.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY 2021 After-Hours earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of 3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.07.

What price target have analysts set for PFE?

14 brokerages have issued 12 month target prices for Pfizer's stock. Their forecasts range from $24.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $40.07 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for Pfizer
or view Wall Street analyst' top-rated stocks.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS), Exxon Mobil (XOM), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Who are Pfizer's key executives?

Pfizer's management team includes the following people:
  • Dr. Albert Bourla D.V.M., DVM, Ph.D., Chairman & CEO (Age 59, Pay $5.84M)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 56, Pay $3.36M)
  • Mr. Frank A. D'Amelio, CFO & Exec. VP of Global Supply (Age 63, Pay $3.84M)
  • Dr. Mikael Dolsten, Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical (Age 62, Pay $3.66M)
  • Ms. Jennifer B. Damico, Sr. VP, Controller & Principal Accounting Officer (Age 53)
  • Ms. Lidia L. Fonseca, Exec. VP and Chief Digital & Technology Officer (Age 52)
  • Mr. Charles E. Triano, Sr. VP of Investor Relations
  • Mr. Douglas M. Lankler, Exec. VP & Gen. Counsel (Age 55)
  • Mr. Rady A. Johnson, Exec. VP and Chief Compliance, Quality & Risk Officer (Age 59)
  • Dr. Alexander Rod MacKenzie, Chief Devel. Officer & Exec. VP of Global Product Devel. (Age 61)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include New York State Teachers Retirement System (0.14%), DNB Asset Management AS (0.06%), Janney Montgomery Scott LLC (0.04%), Strs Ohio (0.04%), KAMES CAPITAL plc (0.04%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Jennifer B Damico, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends for Pfizer
.

Which institutional investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Sarasin & Partners LLP, Polaris Wealth Advisory Group LLC, New York State Teachers Retirement System, Strs Ohio, Gateway Investment Advisers LLC, Avantax Advisory Services Inc., and Crossmark Global Holdings Inc.. Company insiders that have sold Pfizer company stock in the last year include Douglas M Lankler, and Jennifer B Damico.
View insider buying and selling activity for Pfizer
or view top insider-selling stocks.

Which institutional investors are buying Pfizer stock?

PFE stock was bought by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, KAMES CAPITAL plc, Janney Montgomery Scott LLC, TB Alternative Assets Ltd., Founders Capital Management, Capital Investment Advisors LLC, IFM Investors Pty Ltd, and Trinity Legacy Partners LLC. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, Ronald E Blaylock, and Scott Gottlieb.
View insider buying and selling activity for Pfizer
or or view top insider-buying stocks.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $37.29.

How big of a company is Pfizer?

Pfizer has a market capitalization of $207.27 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.